These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8521609)

  • 1. Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine.
    Ziebell J; Shaw-Stiffel T
    Dig Dis; 1995; 13(4):239-50. PubMed ID: 8521609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of liver function: the current situation.
    Van Thiel DH; Hassanein T
    J Okla State Med Assoc; 1995 Jan; 88(1):11-6. PubMed ID: 7897548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver function assessment by drug metabolism.
    Barstow L; Small RE
    Pharmacotherapy; 1990; 10(4):280-8. PubMed ID: 2388874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
    Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
    Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New methods for assessing liver function in infants and children.
    Balistreri WF; A-Kader HH; Setchell KD; Gremse D; Ryckman FC; Schroeder TJ
    Ann Clin Lab Sci; 1992; 22(3):162-74. PubMed ID: 1503384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.
    Tarantino G; Conca P; Capone D; Gentile A; Polichetti G; Basile V
    Eur J Clin Pharmacol; 2006 Aug; 62(8):605-12. PubMed ID: 16841221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function].
    Klinker H; Joeres R; Bomhard M; Keller F; Dorer J; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():52-5. PubMed ID: 7483715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic tests to study liver function.
    Burra P; Masier A
    Eur Rev Med Pharmacol Sci; 2004; 8(1):19-21. PubMed ID: 15209151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function.
    Park GJ; Katelaris PH; Jones DB; Seow F; Le Couteur DG; Ngu MC
    Hepatology; 2003 Nov; 38(5):1227-36. PubMed ID: 14578861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum metabolite/caffeine ratios as a test for liver function.
    Jodynis-Liebert J; Flieger J; Matuszewska A; Juszczyk J
    J Clin Pharmacol; 2004 Apr; 44(4):338-47. PubMed ID: 15051740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the time course of drugs with inhibitory effects on hepatic metabolic activity using successive salivary caffeine tests.
    Soto J; Alsar MJ; Sacristan JA
    Pharmacotherapy; 1995; 15(6):781-4. PubMed ID: 8602388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis.
    Shyu JK; Wang YJ; Lee SD; Lu RH; Lo KJ
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 May; 57(5):329-34. PubMed ID: 8768380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lidocaine and its metabolite as a hepatic function marker in dogs.
    Pérez-Guillé BE; Villegas-Alvarez F; Toledo-López A; Jiménez-Bravo MA; González-Zamora JF; Carrasco-Portugal MC; Flores-Murrieta FJ; Soriano-Rosales RE
    Proc West Pharmacol Soc; 2011; 54():62-5. PubMed ID: 22423583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
    Testa R; Campo N; Caglieris S; Risso D; Alvarez S; Arzani L; Giannini E; Lantieri PB; Celle G
    Hepatogastroenterology; 1998; 45(19):154-9. PubMed ID: 9496506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of smoking on caffeine elimination by the liver in patients with chronic liver diseases].
    Hartleb M; Nowak A; Becker A; Mańczyk I
    Pol Arch Med Wewn; 1990 Dec; 84(6):351-6. PubMed ID: 2092323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.
    Ginsberg G; Hattis D; Russ A; Sonawane B
    J Toxicol Environ Health A; 2004 Feb; 67(4):297-329. PubMed ID: 14713563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dynamic liver function study using the lidocaine test].
    Sídlová K; Průsa R
    Cas Lek Cesk; 2000 Sep; 139(19):604-5. PubMed ID: 11192753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.